Overview

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi-center, open-label, dose-escalation study of DMUC5754A administered as a single agent by intravenous (IV) infusion to patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.